OTCPK:AONC.F

Stock Analysis Report

Executive Summary

Advanced Oncotherapy plc, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Share Price & News

How has Advanced Oncotherapy's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

AONC.F

4.6%

US Healthcare

2.3%

US Market


1 Year Return

n/a

AONC.F

-8.5%

US Healthcare

5.6%

US Market


Shareholder returns

AONC.FIndustryMarket
7 Day0%4.6%2.3%
30 Day0%-0.1%-1.0%
90 Day0%-4.5%-0.7%
1 Yearn/a-7.1%-8.5%7.9%5.6%
3 Year-63.8%-63.8%31.9%26.5%45.6%36.3%
5 Yearn/a63.7%53.9%65.8%47.6%

Price Volatility Vs. Market

How volatile is Advanced Oncotherapy's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Advanced Oncotherapy undervalued compared to its fair value and its price relative to the market?

2x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate AONC.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate AONC.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AONC.F is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: AONC.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate AONC.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AONC.F is good value based on its PB Ratio (2x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is Advanced Oncotherapy forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

25.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AONC.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AONC.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AONC.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AONC.F's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AONC.F's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Advanced Oncotherapy performed over the past 5 years?

-33.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AONC.F is unprofitable, and losses have increased over the past 5 years at a rate of -33.8% per year.

Accelerating Growth: Unable to compare AONC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AONC.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: AONC.F has a negative Return on Equity (-62.09%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: AONC.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AONC.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Advanced Oncotherapy's financial position?


Financial Position Analysis

Short Term Liabilities: AONC.F's short term assets (£13.7M) exceeds its short term liabilities (£9.0M)

Long Term Liabilities: AONC.F's short term assets (13.7M) do not cover its long term liabilities (16.5M)


Debt to Equity History and Analysis

Debt Level: AONC.F's debt to equity ratio (8.8%) is considered satisfactory

Reducing Debt: AONC.F's debt to equity ratio has reduced from 45.7% to 8.8% over the past 5 years.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AONC.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AONC.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.9% each year.


Next Steps

Dividend

What is Advanced Oncotherapy's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate AONC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AONC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AONC.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AONC.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AONC.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Advanced Oncotherapy's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Nicolas Serandour 0

2.8yrs

Tenure

UK£1,214,581

Compensation

Mr. Nicolas Serandour has been the Chief Executive Officer of Advanced Oncotherapy Plc since October 27, 2016. Mr. Serandour served as the Chief Financial Officer and Chief Operating Officer at Advanced On ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Nicolas's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.8yrs

Average Tenure

Experienced Management: AONC.F's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

5.0yrs

Average Tenure

70.5yo

Average Age

Experienced Board: AONC.F's board of directors are considered experienced (5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mike Sinclair (76yo)

    Executive Chairman

    • Tenure: 5.2yrs
    • Compensation: UK£1.18m
  • David Navas

    Vice President of Investor and Public Relations

    • Tenure: 2.7yrs
  • Donatella Ungaro

    Managing Director of ADAM

    • Tenure: 11.2yrs
  • Graham Pughe

    Senior Vice-President of Accounting & IT

    • Tenure: 6.7yrs
  • Nicolas Serandour

    CEO & Executive Director

    • Tenure: 2.8yrs
    • Compensation: UK£1.21m
  • Julian Tokuta

    Head of Procurement

    • Tenure: 5.3yrs
  • Steve Myers (72yo)

    Executive Director

    • Tenure: 2.6yrs
    • Compensation: UK£416.28k
  • Bridget Biggar

    Director of Human Resources

    • Tenure: 2.8yrs
  • Ed Lee

    COO & President of Europe

    • Tenure: 2.2yrs
  • Manuel Gallas

    Director of Technical & Engineering

    • Tenure: 0yrs

Board Members

  • Mike Sinclair (76yo)

    Executive Chairman

    • Tenure: 5.2yrs
    • Compensation: UK£1.18m
  • Hans von Celsing (68yo)

    Senior Independent Director

    • Tenure: 2.6yrs
    • Compensation: UK£30.00k
  • Jay Loeffler

    Member of Medical Advisory Board

    • Tenure: 5.8yrs
  • Enrico Vanni (68yo)

    Non-Executive Director

    • Tenure: 5.8yrs
    • Compensation: UK£30.00k
  • Michael Bradfield (69yo)

    Non-Executive Director

    • Tenure: 6.3yrs
    • Compensation: UK£30.00k
  • Chris Nutting

    Member of Medical Advisory Board

    • Tenure: 1.6yrs
    • Compensation: UK£18.00k
  • Nick Plowman

    Chairman of Medical Advisory Board & Non-Executive Director

    • Tenure: 0yrs
    • Compensation: UK£36.00k
  • Nicolas Serandour

    CEO & Executive Director

    • Tenure: 2.8yrs
    • Compensation: UK£1.21m
  • Steve Myers (72yo)

    Executive Director

    • Tenure: 2.6yrs
    • Compensation: UK£416.28k
  • Peter Sigurd Sjostrand (72yo)

    Vice Chairman

    • Tenure: 1yrs
    • Compensation: UK£10.00k

Company Information

Advanced Oncotherapy plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advanced Oncotherapy plc
  • Ticker: AONC.F
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: UK£80.171m
  • Listing Market Cap: UK£96.702m
  • Shares outstanding: 200.43m
  • Website: https://www.avoplc.com

Number of Employees


Location

  • Advanced Oncotherapy plc
  • 4 Tenterden Street
  • Third Floor
  • London
  • Greater London
  • W1S 1TE
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVOAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPAug 2006
AONC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDAug 2006
R3I1DB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2006

Biography

Advanced Oncotherapy plc, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Rel ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/15 01:03
End of Day Share Price2019/05/17 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.